Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Chinyere E Okpara"'
Autor:
Ali H Alghamdi, Jane C Munday, Gustavo Daniel Campagnaro, Dominik Gurvic, Fredrik Svensson, Chinyere E Okpara, Arvind Kumar, Juan Quintana, Maria Esther Martin Abril, Patrik Milić, Laura Watson, Daniel Paape, Luca Settimo, Anna Dimitriou, Joanna Wielinska, Graeme Smart, Laura F Anderson, Christopher M Woodley, Siu Pui Ying Kelly, Hasan MS Ibrahim, Fabian Hulpia, Mohammed I Al-Salabi, Anthonius A Eze, Teresa Sprenger, Ibrahim A Teka, Simon Gudin, Simone Weyand, Mark Field, Christophe Dardonville, Richard R Tidwell, Mark Carrington, Paul O'Neill, David W Boykin, Ulrich Zachariae, Harry P De Koning
Publikováno v:
eLife, Vol 9 (2020)
Mutations in the Trypanosoma brucei aquaporin AQP2 are associated with resistance to pentamidine and melarsoprol. We show that TbAQP2 but not TbAQP3 was positively selected for increased pore size from a common ancestor aquaporin. We demonstrate that
Externí odkaz:
https://doaj.org/article/04cf21046dd94dac9faba5a20eaa5348
Autor:
Nicoletta Colombo, Domenica Lorusso, Bradley J. Monk, Brian Slomovitz, Kosei Hasegawa, Angélica Nogueira-Rodrigues, Melissa Zale, Chinyere E. Okpara, Gianmaria Barresi, Jodi McKenzie, Vicky Makker
Publikováno v:
Клинический разбор в общей медицине, Vol 4, Iss 12, Pp 62-75 (2023)
Background. Lenvatinib plus pembrolizumab significantly improved efficacy compared with chemotherapy in patients with advanced endometrial cancer (aEC) regardless of microsatellite instability status or histologic subtype, who had disease progression
Externí odkaz:
https://doaj.org/article/710c4a0b98014278bf805931cfc7c196
Autor:
Viktor Grünwald, Thomas Powles, Masatoshi Eto, Evgeny Kopyltsov, Sun Young Rha, Camillo Porta, Robert Motzer, Thomas E. Hutson, María José Méndez-Vidal, Sung-Hoo Hong, Eric Winquist, Jeffrey C. Goh, Pablo Maroto, Tomas Buchler, Toshio Takagi, Joseph E. Burgents, Rodolfo Perini, Cixin He, Chinyere E. Okpara, Jodi McKenzie, Toni K. Choueiri
Publikováno v:
Frontiers in Oncology, Vol 13 (2024)
Externí odkaz:
https://doaj.org/article/3d4ee96893544a25bb56c9e784f1f819
Autor:
Viktor Grünwald, Thomas Powles, Masatoshi Eto, Evgeny Kopyltsov, Sun Young Rha, Camillo Porta, Robert Motzer, Thomas E. Hutson, María José Méndez-Vidal, Sung-Hoo Hong, Eric Winquist, Jeffrey C. Goh, Pablo Maroto, Tomas Buchler, Toshio Takagi, Joseph E. Burgents, Rodolfo Perini, Cixin He, Chinyere E. Okpara, Jodi McKenzie, Toni K. Choueiri
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionThe phase 3 CLEAR study demonstrated that lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (RCC). Prognostic features including presence
Externí odkaz:
https://doaj.org/article/09be4e69130a41858b234cdb2b5887cc
Autor:
Robert J, Motzer, Matthew H, Taylor, Thomas R Jeffry, Evans, Takuji, Okusaka, Hilary, Glen, Gregory M, Lubiniecki, Corina, Dutcus, Alan D, Smith, Chinyere E, Okpara, Ziad, Hussein, Seiichi, Hayato, Toshiyuki, Tamai, Vicky, Makker
Publikováno v:
Expert Review of Anticancer Therapy. 22:383-400
Lenvatinib is an oral multitargeted tyrosine kinase inhibitor that has shown efficacy and manageable safety across multiple cancer types. The recommended starting doses for lenvatinib differ across cancer types and indications based on whether it is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::164f0f73b6d8ad6b532666394cca3b8b
https://doi.org/10.1080/14737140.2022.2039123
https://doi.org/10.1080/14737140.2022.2039123
Publikováno v:
Future Oncology. 17:4249-4261
While survival rates for patients with relapsed/refractory osteosarcoma are low, kinase inhibitors have shown efficacy in its treatment. The multikinase inhibitor lenvatinib, plus ifosfamide and etoposide, showed antitumor activity in a Phase II stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18496eaee373cb1842161ca909223564
https://doi.org/10.2217/fon-2021-0743
https://doi.org/10.2217/fon-2021-0743
Autor:
David R. Shaffer, Matthew H. Taylor, Alvaro Pinto, Daniel Heinrich, Chung-Han Lee, Chinyere E. Okpara, Øyvind Krohn Tennøe, Mehmet Asim Bilen, Donald A. Richards, Jane Wu, Randy F. Sweis, Arpit Rao, Rodolfo F. Perini, Amishi Yogesh Shah, Allen Lee Cohn, Jay Courtright, James J. Hsieh, Emmett V. Schmidt, Sara Gunnestad Ribe, Alan D. Smith, Drew W. Rasco, Robert J. Motzer, Regina Gironés Sarrió, Christopher Di Simone, Sharad Jain, Musaberk Goksel, Peter Kubiak, Nicholas J. Vogelzang
Publikováno v:
LANCET ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Summary Background Despite advances in the first-line treatment of metastatic renal cell carcinoma (RCC), there is an unmet need for options to address disease progression during or after treatment with immune checkpoint inhibitors (ICIs). Pembrolizu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::560f50f96435950099b910b1a10224ee
https://doi.org/10.1016/s1470-2045(21)00241-2
https://doi.org/10.1016/s1470-2045(21)00241-2
Autor:
Rajkumar Venkatramani, Quentin Campbell-Hewson, Nathalie Gaspar, Francisco Bautista, Soledad Gallego Melcon, Alessandra Longhi, Estelle Thebaud, Franco Locatelli, Isabelle Aerts, Michela Casanova, Bruce Morland, Cixin He, Claudia Rossig, Lea Dutta, Adela Cañete Nieto, Chinyere E. Okpara, Stefanie Hecker-Nolting, Perrine Marec-Berard, Sandra J. Strauss, Marion Gambart, Cyril Lervat, Natacha Entz-Werle
Publikováno v:
LANCET ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Background Tyrosine kinase inhibitors have shown activity in osteosarcoma and might enhance the efficacy of chemotherapy. We aimed to determine the recommended phase 2 dose and antitumour activity of lenvatinib with etoposide plus ifosfamide in patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e8c2a8a42f75b5bba44c30b116860c3
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=14716
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=14716
Autor:
Lillian L. Siu, Danny Rischin, Ramona F. Swaby, Lisa Licitra, Cecilia Pinheiro, Kevin J. Harrington, Barbara Burtness, Ezra E.W. Cohen, Makoto Tahara, Jean-Pascal Machiels, Chinyere E. Okpara, Ying Zhu
Publikováno v:
Oral Oncology. 118:7-8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35d6bd52229d3a0230aa372d24d3b746
https://doi.org/10.1016/s1368-8375(21)00375-4
https://doi.org/10.1016/s1368-8375(21)00375-4
Autor:
Anna Dimitriou, Daniel Paape, Christopher M Woodley, Ulrich Zachariae, Anthonius A. Eze, Simone Weyand, Ibrahim A. Teka, Ali H. Alghamdi, Richard R. Tidwell, Arvind Kumar, Jane C. Munday, Juan F. Quintana, Mark Carrington, Mohammed I. Al-Salabi, Paul M. O'Neill, Laura F Anderson, Maria Esther Martin Abril, Harry P. de Koning, Teresa Sprenger, Hasan M. S. Ibrahim, Fredrik Svensson, Simon Gudin, Fabian Hulpia, Patrik Milic, Chinyere E Okpara, Gustavo D. Campagnaro, Dominik Gurvic, Graeme Smart, David W. Boykin, Christophe Dardonville, Luca Settimo, Siu Pui Ying Kelly, Laura Watson, Joanna Wielinska, Mark C. Field
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa648917f3111794e8be1fa4dd747110
https://doi.org/10.7554/elife.56416.sa2
https://doi.org/10.7554/elife.56416.sa2